{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.5","upperLimit":"92.4","value":"86.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Overall response rate is defined as the percentage of participants with a best overall disease response of complete response (CR) or partial response (PR). Response was evaluated per Lugano 2014 classification response criteria. The radiological response is first obtained from CT and PET studies according to the Lugano 2014 criteria. CT response is based on anatomical measurements of index/non-index/new lesions and spleen length. The possible response outcomes are complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). PET response based on a 5-point scale (5PS) or Deauville score. The possible outcomes for PET response are complete metabolic response (CMR), partial metabolic response (PMR), no metabolic response (NMR), or progressive metabolic disease (PMD).","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who were enrolled in the study","id":"OG000","title":"CTL019"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set (EAS): All the patients who received tisagenlecleucel, and had measurable disease at baseline per IRC. Non-measurable disease at baseline is defined as absence of index lesion at baseline disease evaluation (i.e. no disease at baseline).","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Response Rate (ORR) Per IRC Assessment","type":"SECONDARY","unitOfMeasure":"Percentage or participants"}